Opioid Withdrawal’s Potential CV Risk Drives Advisory Panel For Constipation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks advisory committee’s advice on whether cardiovascular outcomes trials for peripherally active mu opioid receptor antagonists should be required and the timing of any such studies.
You may also be interested in...
Naloxegol CV Safety Findings “Reassuring” – NEJM Study
AstraZeneca’s peripherally acting mu-opioid receptor antagonist was not associated with an increased incidence of major cardiovascular events in Phase III studies of chronic pain patients with opioid-induced constipation. An FDA advisory committee will review CV safety data for the drug class June 11-12.
Orexigen Hopes FDA Sees The LIGHT On Contrave NDA
Contrave could be approved by FDA in 2014, making it the third obesity therapeutic to reach the market in the last two years. An interim analysis of the CV outcomes study LIGHT demonstrates a favorable risk-benefit profile, management said.
Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits
Reduction in the risk of hypoglycemia level 2 and 3 events, along with either a reduction or maintenance of an acceptable hemoglobin A1C, is a clinically relevant efficacy endpoint for drug development in Types 1 and 2 diabetes, FDA states in new draft guidance.